Multisystem inflammatory disease in neonates (MIS-N) is a disease of immune dysregulation presenting in the newborn period. Thouvgh its etiopathogenesis is proposed to be similar to multisystem inflammatory disease in Children (MIS-C), the exact pathophysiology is largely unknown as of present. The definition of MIS-N is contentious. The evidence for its incidence, the clinical features, profile of raised inflammatory markers, treatment strategies and outcomes stem from case reports, case series and cohort studies with small sample sizes. Though the incidence of MIS-N in severe acute respiratory syndrome caused by the coronavirus CoVID-2 (SARS-CoV-2) infected asymptomatic neonates is low, its incidence in symptomatic neonates is relatively higher. Further, amongst the neonates who are treated as MIS-N, the mortality rate is high. The review also evaluates the various other unresolved aspects of MIS-N from limited published literature and identifies knowledge gaps which could be areas of future research.

新生儿多系统炎症性疾病（MIS-N）是新生儿期出现的免疫失调疾病。尽管其发病机制被认为与儿童多系统炎症性疾病 (MIS-C) 相似，但目前尚不清楚确切的病理生理学。MIS-N 的定义是有争议的。其发病率、临床特征、升高的炎症标志物概况、治疗策略和结果的证据来自病例报告、病例系列和小样本队列研究。虽然MIS-N在冠状病毒CoVID-2（SARS-CoV-2）感染的无症状新生儿引起的严重急性呼吸系统综合症中的发生率较低，但在有症状的新生儿中发生率相对较高。此外，在接受 MIS-N 治疗的新生儿中，死亡率很高。